Login to Your Account



Earnings Roundup

Vertex Cuts 370 Jobs on Incivek Sales Drop; Hitches Wagon to CF

By Marie Powers
Staff Writer

Wednesday, October 30, 2013
Vertex Pharmaceuticals Inc. faced the music on Incivek (telaprevir), slashing 370 jobs – 15 percent of its work force – after patients turned from the flagging hepatitis C virus (HCV) drug to newer therapies. Revenues from Incivek plummeted to $85.6 million in the third quarter from $254.3 million during the same period a year earlier.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription